PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML

Bibliographic Details
Main Authors:	Brunangelo Falini, Maria Paola Martelli, Riccardo Rossi, Fabio Facchetti, Stefania Zini, Erica Borlenghi, Elena Sabbatini, Lorenzo Brunetti, Daniele Sorcini, Vincenzo Perriello, Enrico Tiacci, Bjorn Gjertsen, Vibeke Andresen
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000973904.73517.87

Similar Items

CD123 Is Consistently Expressed on <i>NPM1</i>-Mutated AML Cells
by: Vincenzo Maria Perriello, et al.
Published: (2021-01-01)

Molecular MRD status and outcome after transplantation in NPM1-mutated AML
by: Dillon, R, et al.
Published: (2020)

A Curious Novel Combination of <i>Nucleophosmin</i> (<i>NPM1</i>) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of <i>NPM1</i> in Acute Myeloid Leukemia (AML)
by: Alessandra Venanzi, et al.
Published: (2021-09-01)

Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
by: Sebastian Schwind, et al.
Published: (2024-03-01)

Significance of NPM1 Gene Mutations in AML
by: Andrew Hindley, et al.
Published: (2021-09-01)

NPM 1 Mutations in AML—The Landscape in 2023
by: Naman Sharma, et al.
Published: (2023-02-01)

NPM is dood, leve NPM!
by: G. J. Van Helden
Published: (2006-11-01)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
by: Maël Heiblig, et al.
Published: (2021-04-01)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
by: Warren Fiskus, et al.
Published: (2022-01-01)

Novel subtypes of NPM1-mutated AML with distinct outcome
by: Arvind Singh Mer, et al.
Published: (2021-07-01)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
by: Rong Wang, et al.
Published: (2022-09-01)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
by: Nigel Russell, et al.
Published: (2023-08-01)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
by: Madlen Jentzsch, et al.
Published: (2023-08-01)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
by: Matthieu Duchmann, et al.
Published: (2022-09-01)

Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?
by: Carlotta Giupponi, et al.
Published: (2023-12-01)

EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML
by: Hala Skayneh, et al.
Published: (2022-03-01)

Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy
by: Isabella Elias Yonezawa Ogusuku, et al.
Published: (2024-06-01)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
by: Claudia Tregnago, et al.
Published: (2021-07-01)

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
by: Arvind Singh Mer, et al.
Published: (2021-02-01)

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
by: Amanda Lopez, et al.
Published: (2021-08-01)

NPM1 deletion is associated with gross chromosomal rearrangements in leukemia.
by: Roberta La Starza, et al.
Published: (2010-01-01)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
by: Hanane Djamai, et al.
Published: (2021-11-01)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
by: Srivasavi Dukka, et al.
Published: (2015-01-01)

From NPM to NWS in Europe
by: Geert Bouckaert
Published: (2022-12-01)

NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes.
by: Anaïs Darracq, et al.
Published: (2019-11-01)

An atypical GABARAP binding module drives the pro-autophagic potential of the AML-associated NPM1c variant
by: Hannah Mende, et al.
Published: (2023-12-01)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
by: A. Hernández-Sánchez, et al.
Published: (2022-06-01)

New public management (NPM) in Malaysia
by: Md. Rozai, Akmal Ahlami
Published: (2016)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
by: Vijay Kumar Singh, et al.
Published: (2019-09-01)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
by: Warren Fiskus, et al.
Published: (2023-04-01)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
by: Daniel Lopes De Menezes, et al.
Published: (2023-08-01)

<i>NPM1</i>-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition
by: Anette Lodvir Hemsing, et al.
Published: (2022-08-01)

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML
by: Anna Wojtuszkiewicz, et al.
Published: (2021-08-01)

Study of HOTAIR LncRNA in AML patients in context to FLT3-ITD and NPM1 mutations status
by: Mona Salah, et al.
Published: (2021-06-01)

RDK 253 (NPM 051) - Pengurusan Muzium
by: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Published: (1995)

NPM-ALK gene fusion and Hodgkin's disease.
by: Waggott, W, et al.
Published: (1997)

P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
by: Ecmel Mehmetbeyoglu, et al.
Published: (2023-08-01)

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML
by: Dyantha I. van der Lee, et al.
Published: (2021-10-01)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
by: Jan Braune, et al.
Published: (2022-01-01)

Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM.
by: Barbora Brodská, et al.
Published: (2017-01-01)